Clinical trial
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain…
NCT00415363 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00415363 |
|---|---|
| Title | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy |
| Official title | A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Cancer, Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | enzastaurin, placebo |
| Enrollment | 109 |
| Start date | Dec 1, 2006 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Dec 22, 2006 |
| Last update posted | Nov 5, 2020 |
| Countries | Denmark, Norway, Poland, Romania, Sweden |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: